Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoquinone for early Parkinson's disease
ACTRN12606000218594Phase 2Active, not recruiting
- Sponsor
- Antipodean Pharmaceuticals, Inc.
- Start
- May 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of mitoquinone in Parkinson's disease (PD) (3 arms), sponsored by Antipodean Pharmaceuticals, Inc. Primary endpoint: Change in total Unified Parkinson's Disease Rating Scale score. Started May 2006; status: active, not recruiting.
02
Drugs
mitoquinone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ACTRN12606000218594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000218594.